Pancreatic Cancer Research

ResearcherHerlev HospitalActive in the last 2 years

Susann Theile

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9804-7744; OpenAlex author ID A5071040943. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 2 papers

Papers 11

  1. Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. First author DOI 10.1002/iid3.70545↗
  2. Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates. Co-author DOI 10.1038/s41392-026-02626-3↗
  3. A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE). First author DOI 10.1016/j.iotech.2025.101054↗
  4. Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. Co-author DOI 10.1126/sciadv.ads5002↗
  5. Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Surviva… Co-author DOI 10.1200/jco-25-01631↗
  6. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cac… Co-author DOI 10.1200/jco.23.01965↗
  7. Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2024.103489↗
  8. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Co-author DOI 10.1016/j.ejca.2022.11.035↗
  9. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherap… Co-author DOI 10.3389/fimmu.2023.1228907↗
  10. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (Che… Co-author DOI 10.1200/jco.21.02511↗
  11. A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic C… Co-author DOI 10.3390/pharmaceutics14030509↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Inna Markovna Chen · 9 shared papers, 2022–2026 · strength 1.78
  2. Julia Sidenius Johansen · 8 shared papers, 2022–2026 · strength 1.63
  3. Dorte Lisbet Nielsen · 8 shared papers, 2022–2025 · strength 1.50
  4. Mads Hald Andersen · 2 shared papers, 2026 · strength 0.63
  5. Katherine R. Pelz · 2 shared papers, 2025 · strength 0.41
  6. Denis C. Guttridge D · 2 shared papers, 2025 · strength 0.41
  7. Teresa A Zimmers · 2 shared papers, 2025 · strength 0.41
  8. Olav Faisal Dajani · 2 shared papers, 2025 · strength 0.41
  9. Michael C. Ostrowski · 2 shared papers, 2025 · strength 0.41
  10. Estrid Vilma Solyom Høgdall · 2 shared papers, 2023–2025 · strength 0.41
  11. Inna M. Chen · 1 shared paper, 2026 · strength 0.33
  12. Laura Kofoed Kjær · 1 shared paper, 2026 · strength 0.33
  13. Jessica Xin Hjaltelin · 2 shared papers, 2022–2023 · strength 0.31
  14. Søren Brunak · 2 shared papers, 2022–2023 · strength 0.31
  15. Rasmus Erik Johansson Mortensen · 1 shared paper, 2026 · strength 0.30
  16. Josephine Hallundbæk Ruders · 1 shared paper, 2026 · strength 0.30
  17. I.M. Chen · 1 shared paper, 2024 · strength 0.22
  18. Sidsel C. Lindgaard · 1 shared paper, 2024 · strength 0.22
  19. Troels Dreier Christensen · 1 shared paper, 2024 · strength 0.22
  20. Carolyn Hruban · 1 shared paper, 2025 · strength 0.20
  21. Victor E. Velculescu · 1 shared paper, 2025 · strength 0.20
  22. Astrid Zedlitz Johansen · 1 shared paper, 2023 · strength 0.18
  23. Carsten Palnæs Hansen · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.